What Ananda Pharma does

Ananda Pharma is a clinical-stage biopharmaceutical company developing non-psychoactive CBD-based therapeutics. Its lead asset, MRX1 CBD Oral Solution, is being advanced through clinical trials for two indications: endometriosis-associated pain (targeting ~190 million women globally) and chemotherapy-induced peripheral neuropathy (CIPN). The company completed a Phase 1 pharmacokinetic study in June 2026 demonstrating favorable safety and tolerability across two dose levels, with all treatment-emergent adverse events classified as mild and no serious events reported. In March 2026, Ananda received MHRA and NHS Health Research Authority Ethics Committee approval to initiate the ENDOCAN Phase 2 trial, which will randomize up to 100 women over a 12-week treatment period across NHS Lothian and NHS Grampian in Scotland, with Phase 2 dosing planned for H2 2026.

The company is pre-revenue and operates a pharmaceutical drug development and commercialization model, with future revenue contingent on regulatory approval and commercial launch in endometriosis pain and CIPN indications. Its underlying technology centers on a proprietary high-dose CBD oral solution formulation. The company also holds SME (small or medium-sized enterprise) qualification at the European Medicines Agency (EMA) in London and has received development funding from the European Union through the European Regional Development Fund (Europäischer Fonds für Regionale Entwicklung). Following the April 2026 U.S. rescheduling of FDA-approved cannabis medicines from Schedule I to Schedule III — which facilitates easier banking access — Ananda is preparing to raise $10–20 million in private funding to accelerate U.S. regulatory engagement and manufacturing. Leadership is anchored by Managing Director (Geschäftsführer) Yatin Shah, and clinical operations are run through NHS partnerships rather than a commercial sales force.

Note: Source data references two entities sharing the Ananda Pharma name — Ananda Pharma GmbH (Potsdam, Germany; HRB 26894), focused on diagnostic tests and sustainable cultivation of pharmaceutically usable plants, and the UK-based biopharmaceutical entity advancing MRX1 through clinical trials. The dominant investment narrative is the UK biopharmaceutical entity, but the corporate structure should be verified.

Name

Ananda Pharma

Legal name

Ananda Pharma GmbH

Website

https://anandapharma.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Ananda Pharma is a clinical-stage biopharmaceutical company developing MRX1, a proprietary non-psychoactive CBD oral solution for endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. Pre-revenue, the UK-based company is preparing a $10–20 million private funding round to advance U.S. regulatory and manufacturing scale-up.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain

Revenue model

1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical stage company developing proprietary CBD-based therapeutic. Revenue will be generated from drug commercialization upon regulatory approval for endometriosis pain and chemotherapy-induced peripheral neuropathy indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ananda Pharma develops innovative therapeutics through proprietary CBD oral solution formulations (lead asset MRX1) targeting endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. The company also develops diagnostic medical devices and pursues sustainable cultivation of pharmaceutically usable plants. It is qualified as an SME at the European Medicines Agency and is advancing its lead asset through Phase 2 clinical trials.

Product overview

Ananda Pharma is a UK-based biopharmaceutical company focused on developing innovative CBD-based medicines. The company's primary product is MRX1 CBD Oral Solution, a proprietary non-psychoactive CBD drug formulation. Currently, Ananda Pharma is advancing MRX1 through clinical development, with an ENDOCAN Phase 2 clinical trial approved for investigating the drug's efficacy for endometriosis pain, and plans for Phase 2 trials targeting chemotherapy-induced peripheral neuropathy. The company operates with a mission to address unmet medical needs in chronic pain conditions through cannabis-derived therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• MRX1 CBD Oral Solution Proprietary non-psychoactive CBD (cannabidiol) oral solution developed for the treatment of endometriosis-associated pain and chemotherapy-induced peripheral neuropathy; targets chronic pain indications with significant unmet medical need and has completed Phase 1 with a favorable safety profile.
• Diagnostic Medical Devices and Tests Diagnostic medical devices and tests being developed alongside drug formulations by Ananda Pharma GmbH for pharmaceutical and clinical applications.

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• NHS LothiancoreStrategic or Co-development Partner · 4 March 2026NHS Lothian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial will randomize women over a 12-week treatment period.
• NHS GrampiancoreStrategic or Co-development Partner · 4 March 2026NHS Grampian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial is part of the ENDOCAN Phase 2 clinical program.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz Pharmaceuticals owns GW Pharmaceuticals, which developed Epidiolex, the first FDA-approved CBD prescription drug. Ananda's MRX1 CBD oral solution follows the same cannabinoid pharmaceutical model, targeting specific indications in the regulatory pathway GW pioneered.
• Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company developing transdermal CBD (ZYN002) for indications including Fragile X syndrome and other CNS conditions. Direct peer as a CBD-based pharmaceutical targeting unmet medical needs via the regulatory pathway.
• InMed Pharmaceuticals: Cannabinoid pharmaceutical-focused biotech developing proprietary cannabinoid APIs (INM-901) for neurological and dermatological indications. Comparable in being a small, pre-commercial cannabinoid pharma pursuing the regulated drug approval route.
• Botanix Pharmaceuticals: Clinical-stage cannabinoid pharmaceutical company developing prescription therapeutics (e.g., BTX 1801, BTX 1703) for dermatology and antimicrobial indications. Direct peer in clinical-stage cannabinoid drug development targeting regulated prescription markets.

Emerging players

• Myovant Sciences (Sumitomo Pharma): Developer of Myfembree (relugolix combination) approved for endometriosis-associated pain. Direct comparator for Ananda's lead indication; differs in mechanism but competes for the same physician and patient population.

Broad incumbents

• AbbVie: Marketer of Orilissa (elagolix), the first FDA-approved oral GnRH antagonist for endometriosis pain. Larger pharma incumbent in Ananda's lead indication, defining the standard of care Ananda would compete against.
• Tilray Brands: Major global cannabis company with a growing pharmaceutical/medical division. Broad incumbent in cannabis therapeutics and a likely competitor for any Ananda commercial partnership or distribution arrangement.
• Canopy Growth Corporation: Large cannabis company with medical/pharmaceutical product lines (e.g., Spectrum Therapeutics). Broad incumbent that develops and distributes cannabinoid-based therapeutics, providing scale comparison for Ananda's niche CBD pharma strategy.
• Charlottes Web Holdings: Vertically integrated CBD therapeutics company with a broad hemp-derived CBD product portfolio focused on wellness and clinical indications (e.g., seizure disorders, sleep, pain). Comparable as a CBD-focused therapeutic brand pursuing clinical substantiation.
• Cronos Group: Global cannabinoid company with pharmaceutical partnerships (e.g., with Ginkgo Bioworks) and consumer CBD products. Broad incumbent investing in cannabinoid pharmaceutical science, relevant as a larger-scale counterpart in regulated cannabis-based therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ananda-pharma-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ananda Pharma